Brought to you by 
OSI buys Eyetech for $892.4mm
31 Jan 2008
Executive Summary
To move into the ophthalmic arena, cancer and diabetes drug company OSI Pharmaceuticals is acquiring all the outstanding shares of publicly traded Eyetech Pharmaceuticals for about $892.4mm in cash and stock.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com